Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
About Us
Investor
Subsidiary
Management Team
Cooperate History
 
Cooperate History
March, 2019 FDZJ has transferred rights of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection, which was independently developed by FDZJ, to a third-party.

December, 2018 As a subsidiary of FDZJ, Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. was identified as “Hi-Tech Enterprise” by Jiangsu Government.

July, 2018 As class I biological product, “Recombinant Anti-CD30 Human-mouse Chimeric Monoclonal” has achieved Clinical Trial Permission with approval number of 2018L02789.

April, 2018 FDZJ was awarded “Outstanding Contribution to Economy” by Pudong New Area People’s Government.

February, 2018 Shanghai Bao Su Pharmaceutical Technology Co. , Ltd was established as a subsidiary of FDZJ.

December, 2017 FDZJ was continuously recognized as Shanghai Enterprise Technology Center.

October,2017 After two years efforts, FDZJ successfully achieved IPMS.

October, 2017 FDZJ was continuously identified as “Hi-Tech Enterprise” by Shanghai Municipal Government.

January, 2017 “Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection” was approved to conduct clinical trial by CFDA.

December, 2016 FDZJ announced that the new drug Hemoporfin for injection went on sale.

November, 2016 Twenty year anniversary and team building training of FDZJ were held in Shanghai Sheshan, the theme was “20 years on, the story isn’t over”.

October, 2016 In October 2016, FDZJ has obtained drug approval issued by China Food and Drug Administration for Hemoporfin for injection, which number is Guo Yao Zhun Zi H20163349.

April, 2016 Air conditioning system design of small capacity injection workshop won the “best equipment innovation award” at 2016 ISPE China Annual Spring Conference.

July, 2015 Derma Care Clinic Medical investment and management Co., Ltd was established as a subsidiary of FDZJ.

June, 2015 The company was recognized as Shanghai model enterprise of patent work.

October, 2014 The company was recognized as Shanghai Enterprise Technology Center.

October, 2014 The company's photodynamic therapy drug "Aminolevulinic Acid Hydrochloride" (118mg/vial) (ALA®) project has been certified as national strategic innovative product in national key new product plan of the Ministry of Science and Technology.

September, 2014 FDZJ was selected by 2014 Forbes Asia as one of the “Best Under A Billion” corporations.

June, 2014 Two subjects, “Core Technology Buildup and Product Development of Antibody Conjugate Drugs” and “Research and Development of Key Variety of Photodynamic Creative Drugs”, have been selected “Significant New Drug Creation” in national key scientific program.

December, 2013 Transfer of listing of the H shares from GEM to the main board of The Stock Exchange of Hong Kong Limited, and new stock code is 1349.

August, 2013 The Prizes of "2012 Top Ten Projects of Shanghai High-tech Achievement Conversion based on Independent Innovation" and "2012 Hundred Best Projects of Shanghai High and New Technology Achievement Conversion” were rewarded to FDZJ in August 2013, due to the product of Aminolevulinic acid hydrochloride (ALA®)independently developed by the company, and the product ranks the first place on both rewards.

December, 2012 Category I New Drug,Hemoporfin obtained the new drug certificate issued by China Food and Drug Administration.

November, 2012 Shanghai Tracing Biotech Co., Ltd. was established as a subsidiary of FDZJ.

Feburary, 2011 A strategic cooperation agreement on innovative drug research and development (R&D) was signed between Shanghai Pharmaceuticals Holding Co., Ltd. and FDZJ.

August, 2010 Category I New Drug :Hemoporfin was completed clinical trial and was submitted for application of new drug certificate.

February, 2010 The paper “Reconbinant Mutant Human Tumor Necrosis Factor Receptor-FC Fusion Protein in Development” by FDZJ was published in the Science Journal of United States.

December, 2009 FDZJ was selected by the National Science and Technology Program as “Significant New Drug Creation –Enterprises Innovation Incubation Base” with funding support.

October, 2008 Drug license for “The Doxorubicin Hydrochloride Liposome Injection (LIBOd®) was issued by SFDA in October 2008 and sale started thereafter.

March, 2007 FDZJ established a wholly-owned subsidiary, Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. in Jiangsu province.

March, 2007 Nifivoc, a drug for the treatment of HIV/AIDS was approved to conduct the clinical trial by the SFDA.

February, 2007 Drug License for Aminolevulinic Acid(ALA®)issued by SFDA in February 2007 and sale started thereafter.

November, 2006 Ten year anniversary celebration of FDZJ was held.

October, 2005 FDZJ completed the first clinical trial of Aminolevulinic Acid(ALA®).

July, 2004 FDZJ was awarded the national GMP certification of the SFDA.

March, 2004 “Down Syndrome Prenatal Screening System” was approved by SFDA. It is the first drug selected by the national “Birth Defects Intervention Project” .

March 2004 Drug technology was transferred to oversea firm for the first time.

June, 2003 Shanghai Ba Dian Medicine Co., Ltd. was established as a subsidiary of FDZJ.

December, 2002 Shanghai Lead Discovery Limited Company was established as an associate of FDZJ.

August, 2002 IPO in Hong Kong GEM, stock code: 8231.

July, 2002 The new research and development base was built with full function.

June, 2002 The first new drug “Recombinant human lymphotoxin α-derivatives (LT)” was approved to conduct clinical trial.

December, 2001 FDZJ undertook the National High Technology Research and Development Program (863 Program).

October, 2000 FDZJ was transformed into a joint stock company with limited liability, and the full name is “Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.”.

September, 2000 China General Technology (Group) Holding Co., Ltd. became the second largest shareholder through an equity transaction. The share has been transferred to China New Enterprise Investment Fund II on 27 Feb.2013.

March, 2000 FDZJ undertook the National Key Science and Technology Project Plan project.

August, 1999 Shanghai Pharmaceuticals Holding Co., Ltd. (SH600849) became the largest shareholder through an equity transaction.

May, 1999 FDZJ was designated as “Enterprise Postdoctoral Research Workstation” by the Ministry of Human Resources of PPC.

November, 1998 FDZJ was identified as “Hi- Tech Enterprise” by Shanghai Municipal Government.

August, 1998 FDZJ established Shanghai Morgan-Tan International Center for Life Science Co., Ltd. as a subsidiary.

December, 1997 Shanghai Zhangjiang Hi-tech Park Development Co., Ltd. (SH600895) became a new investor of FDZJ.

November, 1996 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.(FDZJ) was established in November 1996, by Fudan University, Shanghai Pudong New District Economy and Trade State-own Asset Management Co., Ltd. and Zhangjiang Hi-tech Promotion Centre.

Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2015-0015    沪ICP备10027510号-1